期刊文献+

Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient 被引量:3

Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
下载PDF
导出
摘要 A 55-year-old male patient with hepatitis B-related liver cirrhosis was found to have advanced hepatocellular carcinoma.His AFP was initially 9828μg/L and rapidly dropped to 5597μg/L in ten days after oral sorafenib treatment.However,he developed acute renal failure, hyperkalemia,and hyperuricemia 30 d after receiving the sorafenib treatment.Tumor lysis syndrome was suspected and intensive hemodialysis was performed. Despite intensive hemodialysis and other supportive therapy,he developed multiple organ failure(liver, renal,and respiratory failure)and metabolic acidosis. The patient expired 13 d after admission. A 55-year-old male patient with hepatitis B-related liver cirrhosis was found to have advanced hepatocellular carcinoma. His AFP was initially 9828 μg/L and rapidly dropped to 5597 μg/L in ten days after oral sorafenib treatment. However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment. Tumor lysis syndrome was suspected and intensive hemodialysis was performed. Despite intensive hemodialysis and other supportive therapy, he developed multiple organ failure (liver, renal, and respiratory failure) and metabolic acidosis. The patient expired 13 d after admission.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第35期4464-4466,共3页 世界胃肠病学杂志(英文版)
关键词 综合征 肝癌 溶解 肿瘤 患者 急性肾功能衰竭 代谢性酸中毒 血液透析 Sorafenib Tumor lysis syndrome Hepato-cellular carcinoma Hemodialysis Hyperkalemia
  • 相关文献

参考文献10

  • 1Wilhelm SM,Carter C,Tang L,Wilkie D,McNabola A,Rong H,Chen C,Zhang X,Vincent P,McHugh M,Cao Y,Shujath J,Gawlak S,Eveleigh D,Rowley B,Liu L,Adnane L,Lynch M,Auclair D,Taylor I,Gedrich R,Voznesensky A,Riedl B,Post LE,Bollag G,Trail PA.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res 2004; 64:7099-7109.
  • 2FDA approves Nexavar for patients with inoperable liver cancer.Available from:URL:http://www.fda.gov/bbs/topics/NEWS/2007/NEW01748.html.Retrieved December 3,2007.
  • 3Abou-Alf a GK,Schwartz L,Ricci S,Amadori D,Santoro A,Figer A,De Greve J,Douillard JY,Lathia C,Schwartz B,Taylor I,Moscovici M,Saltz LB.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.J Clin Oncol 2006; 24:4293-4300.
  • 4Liu L,Cao Y,Chen C,Zhang X,McNabola A,Wilkie D,Wilhelm S,Lynch M,Carter C.Sorafenib blocks the RAF/ MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.Cancer Res 2006; 66:11851-11858.
  • 5Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,H(a)ussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 2008; 359:378-390.
  • 6Davidson MB,Thakkar S,Hix JK,Bhandarkar ND,Wong A,Schreiber MJ.Pathophysiology,clinical consequences,and treatment of tumor lysis syndrome.Am J Med 2004; 116:546-554.
  • 7Rampello E,Fricia T,Malaguarnera M.The management of tumor lysis syndrome.Nat Clin Pract Oncol 2006; 3:438-447.
  • 8Gobel BH.Management of tumor lysis syndrome:prevention and treatment.Semin Oncol Nurs 2002; 18:12-16.
  • 9Cairo MS,Bishop M.Tumour lysis syndrome:new therapeutic strategies and classification.Br J Haematol 2004; 127:3-11.
  • 10Schelling JR,Ghandour FZ,Strickland TJ,Sedor JR.Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis:case report and a review of the literature.Ren Fail 1998; 20:635-644.

同被引文献8

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部